Euroopa Liit -
eesti -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
Eesti -
eesti -
Adama
tomahawk® 200 ec
adama - emulsioonikontsentraat - fluroksüpüür - herbitsiidid
Eesti -
eesti -
Adama
poleposition® ja mirador® segu
adama - emulsioonikontsentraat / suspensioonikontsentraat - asoksüstrobiin + protiokonasool - fungitsiidid
Eesti -
eesti -
Adama
legacy® 500 sc
adama - suspensioonikontsentraat - diflufenikaan - herbitsiidid
Eesti -
eesti -
Adama
mirador® 250 sc
adama - suspensioonikontsentraat - asoksüstrobiin - fungitsiidid
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.